Most patients with RA have a prolonged disease course and a high disability rate in the early 2-3 years, with up to 70% joint destruction within 3 years if not treated early and reasonably. Active and correct treatment can lead to remission in more than 80% of RA patients, and only a few eventually become disabled. There are no accurate indicators to predict prognosis, but it is usually believed that: males have a better prognosis than females; those with late onset have a better prognosis than those with early onset; the number of joints involved at the onset of disease or with metatarsophalangeal joints involved, or the cumulative number of joints greater than 20 during the course of disease has a poor prognosis; persistent high titer rheumatoid factor positivity, persistent rapid blood sedimentation, increased C-reactive protein, and increased eosinophils in the blood indicate a poor prognosis; and the presence of severe Systemic symptoms (fever, anemia, malaise) and extra-articular manifestations (rheumatoid nodules, sclerositis, interstitial lung disease, pericardial disease, systemic vasculitis and other visceral injuries) indicate a poor prognosis; those whose symptoms are difficult to control with short-term hormone therapy or whose maintenance dose of hormone cannot be reduced to less than 10 mg/day have a poor prognosis. In addition, the early and late treatment and the rationality of the treatment plan have an important impact on the prognosis.